F S&P 500
5,211.75 -2.00 (-0.04%) F Dow Jones
39,006.00 -21.00 (-0.05%) F Nasdaq
18,200.75 +1.25 (+0.01%) E-mini Russell 2000 Index Futur
2,071.40 -5.30 (-0.26%) Petróleo
78.11 -0.27 (-0.34%) Oro
2,318.30 -5.90 (-0.25%)
Comera Life Sciences Holdings, Inc. (CMRA)
Comera Life Sciences Holdings, Inc.
12 Gill Street
Suite 4650
Woburn, MA 01801
United States
617 871 2101
https://comeralifesciences.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 12
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael G. Campbell CPA | CEO, CFO & Principal Accounting Officer | 269.11k | N/D | 1969 |
| Dr. David Soane Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/D | N/D | N/D |
| Ms. Janice Marie McCourt B.S., CLP, M.B.A., R.Ph. | Chief Business Officer | N/D | N/D | 1962 |
Descripción
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Comera Life Sciences Holdings, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
